Crews Bank & Trust Makes New Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Crews Bank & Trust purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, Holdings Channel reports. The firm purchased 690 shares of the medical equipment provider’s stock, valued at approximately $360,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical in the 4th quarter worth $26,000. Godsey & Gibb Inc. lifted its holdings in shares of Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares during the period. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical during the 3rd quarter worth about $33,000. Decker Retirement Planning Inc. bought a new position in shares of Intuitive Surgical during the 4th quarter worth about $36,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Intuitive Surgical during the 3rd quarter worth about $38,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ISRG shares. CICC Research started coverage on shares of Intuitive Surgical in a report on Monday. They set a “neutral” rating and a $550.00 price objective for the company. Jefferies Financial Group raised their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a report on Monday. Barclays raised their price objective on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday. UBS Group lifted their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a report on Monday. Finally, Citigroup lifted their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Trading Up 1.3 %

ISRG opened at $580.18 on Friday. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The firm has a 50-day moving average price of $549.32 and a two-hundred day moving average price of $507.50. The stock has a market capitalization of $206.65 billion, a PE ratio of 93.28, a PEG ratio of 5.19 and a beta of 1.39.

Insider Transactions at Intuitive Surgical

In other news, insider Jamie Samath sold 269 shares of Intuitive Surgical stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at $4,727,816.73. The trade was a 2.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. This represents a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,843 shares of company stock worth $15,357,560 in the last quarter. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.